BeiGene's (HKG:6160, SHA:688235) loss narrowed to $151.9 million in the fourth quarter of 2024 from $367.6 million in the year-ago period.
Loss per share at the drug company narrowed to $0.11 from $0.27 in the previous year, according to a Thursday filing with the Hong Kong bourse.
Total revenue surged to $1.12 billion from $630.5 million a year earlier.
For 2025, full-year revenue is seen to range between $4.9 billion and $5.3 billion. It also forecasts positive GAAP operating income, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.